

Lucia Taramasso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5565011/publications.pdf>

Version: 2024-02-01

105
papers

2,615
citations

304743

22
h-index

214800

47
g-index

109
all docs

109
docs citations

109
times ranked

4785
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade. <i>HIV Medicine</i> , 2022, 23, 70-79.	2.2	11
2	Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children. <i>BMC Infectious Diseases</i> , 2022, 22, 55.	2.9	2
3	<i>Aspergillus</i> PCR in bronchoalveolar lavage –diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patients. <i>Mycoses</i> , 2022, 65, 411-418.	4.0	10
4	Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 472-479.	1.1	2
5	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2021-055289.	1.9	1
6	Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment. <i>Frontiers in Immunology</i> , 2022, 13, 847816.	4.8	2
7	<i>Pneumocystis jirovecii</i> pneumonia in HIV-negative patients, a frequently overlooked problem. A case series from a large Italian center. <i>International Journal of Infectious Diseases</i> , 2022, 121, 172-176.	3.3	5
8	Reversibility of Central Nervous System Adverse Events in Course of Art. <i>Viruses</i> , 2022, 14, 1028.	3.3	8
9	Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression. <i>Vaccines</i> , 2022, 10, 1141.	4.4	11
10	Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. <i>Journal of Nephrology</i> , 2021, 34, 173-183.	2.0	52
11	Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1664-1665.	3.3	3
12	Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view. <i>Tuberculosis</i> , 2021, 126, 102041.	1.9	1
13	Spread of Carbapenem-Resistant Gram-Negatives and <i>Candida auris</i> during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship?. <i>Microorganisms</i> , 2021, 9, 95.	3.6	77
14	Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 119-127.	2.1	15
15	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 387-398.	4.0	11
16	Injectable Antiretroviral Drugs: Back to the Future. <i>Viruses</i> , 2021, 13, 228.	3.3	7
17	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 555.	2.4	93
18	The impact of DAA-mediated HCV eradication on CD4 ⁺ and CD8 ⁺ T lymphocyte trajectories in HIV/HCV coinfecting patients: Data from the ICONA Foundation Cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 779-786.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity. <i>PLoS Pathogens</i> , 2021, 17, e1009448.	4.7	43
20	Weight gain and aging in people with HIV. <i>Aids</i> , 2021, 35, 987-989.	2.2	2
21	Duration of isolation and precautions in immunocompromised patients with COVID-19. <i>Journal of Hospital Infection</i> , 2021, 111, 202-204.	2.9	10
22	Evaluating fostemsavir as a therapeutic option for patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1539-1545.	1.8	1
23	Real-World Analysis of Survival and Clinical Events in a Cohort of Italian Perinatally HIV-1 Infected Children From 2001 to 2018. <i>Frontiers in Pediatrics</i> , 2021, 9, 665764.	1.9	6
24	Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care. <i>European Journal of Internal Medicine</i> , 2021, 94, 39-44.	2.2	8
25	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , 2021, 35, 342-353.	2.5	15
26	Starting HIV therapy in patients with mitochondrial disease. <i>Aids</i> , 2021, 35, 2063-2065.	2.2	0
27	How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis. <i>Journal of Clinical Virology</i> , 2020, 123, 104255.	3.1	18
28	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. <i>PLoS ONE</i> , 2020, 15, e0240550.	2.5	2
29	Factors associated with hospital admission for COVID-19 in HIV patients. <i>Aids</i> , 2020, 34, 1983-1985.	2.2	26
30	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13358.	3.4	4
31	Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. <i>Journal of Clinical Medicine</i> , 2020, 9, 2780.	2.4	71
32	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. <i>PLoS ONE</i> , 2020, 15, e0237831.	2.5	85
33	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. <i>Microorganisms</i> , 2020, 8, 2010.	3.6	8
34	Bloodstream infections in critically ill patients with COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13319.	3.4	203
35	Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents: A 10-Year Observational Study. <i>Microorganisms</i> , 2020, 8, 864.	3.6	7
36	Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: a question needing an answer. <i>Journal of Hospital Infection</i> , 2020, 105, 404-405.	2.9	39

#	ARTICLE	IF	CITATIONS
37	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (IN ACTION) cohort. <i>HIV Medicine</i> , 2020, 21, 523-535.	2.2	6
38	Factors Associated With Weight Gain in People Treated With Dolutegravir. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa195.	0.9	47
39	The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. <i>Aids</i> , 2020, 34, 877-881.	2.2	47
40	Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study. <i>BMC Public Health</i> , 2020, 20, 734.	2.9	15
41	Migrants and imported disease: Trends of admission in an Italian infectious disease ward during the migration crisis of 2015â€“2017. <i>BMC Public Health</i> , 2020, 20, 738.	2.9	1
42	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0
43	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. , 2020, 15, e0237831.		0
44	Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1443-1446.	6.0	8
45	HIV-Associated Neurocognitive Impairment in the Modern ART Era: Are We Close to Discovering Reliable Biomarkers in the Setting of Virological Suppression?. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 187.	3.4	55
46	Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. <i>PLoS ONE</i> , 2019, 14, e0223181.	2.5	22
47	Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). <i>AIDS Research and Therapy</i> , 2019, 16, 21.	1.7	5
48	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	3.0	14
49	<p>Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1385-1391.	2.7	19
50	Is it time to re-think the use of etravirine in patients with available genotypic resistance test?. <i>Infectious Diseases</i> , 2019, 51, 452-455.	2.8	2
51	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	13.7	627
52	Immunonutrition in Human Immunodeficiency Virus Infection: Which Populations to Target?. <i>Clinical Infectious Diseases</i> , 2019, 69, 2228-2229.	5.8	0
53	Missed opportunities to prevent motherâ€™toâ€™child transmission of HIV in Italy. <i>HIV Medicine</i> , 2019, 20, 330-336.	2.2	7
54	Bloodstream infections in patients living with HIV in the modern cART era. <i>Scientific Reports</i> , 2019, 9, 5418.	3.3	6

#	ARTICLE	IF	CITATIONS
55	Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821882165.	1.5	4
56	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. <i>Journal of Virus Eradication</i> , 2019, 5, 47-49.	0.5	0
57	HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 189-193.	1.4	3
58	Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience. <i>Journal of Women and Aging</i> , 2019, 31, 176-188.	1.0	0
59	Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2019, 13, 190-197.	0.8	2
60	Immunological profile of an infant treated with integrase inhibitor from the neonatal period. <i>Journal of Virus Eradication</i> , 2019, 5, 47-49.	0.5	0
61	Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing. <i>ERJ Open Research</i> , 2018, 4, 00108-2017.	2.6	5
62	CD8+CD28 ^{hi} CD127 ^{lo} CD39 ⁺ regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection?. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2220-2233.e4.	2.9	22
63	Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 168-170.	1.1	1
64	Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV. <i>Frontiers in Immunology</i> , 2018, 9, 2447.	4.8	1
65	Treatment of hepatitis C virus genotype 4 in the DAA era. <i>Virology Journal</i> , 2018, 15, 180.	3.4	16
66	Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2018, 13, 3-11.	0.8	18
67	How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy. <i>BMC Health Services Research</i> , 2018, 18, 691.	2.2	7
68	Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients. <i>Current Hypertension Reviews</i> , 2018, 14, 48-55.	0.9	2
69	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018, 19, 475-484.	2.2	13
70	Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment. <i>Aids</i> , 2018, 32, 1202-1203.	2.2	0
71	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	3.0	29
72	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). <i>BMC Infectious Diseases</i> , 2018, 18, 357.	2.9	42

#	ARTICLE	IF	CITATIONS
73	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS ONE, 2018, 13, e0192627.	2.5	6
74	Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature. Clinical Nephrology Case Studies, 2018, 6, 31-35.	0.7	3
75	Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients. Journal of Hypertension, 2017, 35, 409-416.	0.5	21
76	Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e76-e79.	1.5	7
77	Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study. Epidemiology and Infection, 2017, 145, 1658-1669.	2.1	5
78	Control of the HIV-1 DNA Reservoir Is Associated<i>In Vivo</i> and<i>In Vitro</i> with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells. Journal of Virology, 2017, 91, .	3.4	39
79	Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?. BMC Infectious Diseases, 2017, 17, 127.	2.9	4
80	Weight Gain: A Possible Side Effect of All Antiretrovirals. Open Forum Infectious Diseases, 2017, 4, ofx239.	0.9	68
81	Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). Journal of Antimicrobial Chemotherapy, 2017, 72, dkw557.	3.0	62
82	Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era: Neglected no more?. PLoS Neglected Tropical Diseases, 2017, 11, e0005237.	3.0	22
83	Role of Raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents. New Microbiologica, 2017, 40, 227-233.	0.1	3
84	Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study. Infection, 2016, 44, 589-597.	4.7	39
85	Chemotherapy Mass Campaigns and Migratory Flows: An Unexpected Connection. Clinical Infectious Diseases, 2016, 62, 1323.1-1323.	5.8	2
86	Onychomadesis in a male patient with secondary syphilis. International Journal of STD and AIDS, 2016, 27, 704-705.	1.1	2
87	Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. International Journal of Antimicrobial Agents, 2016, 48, 551-554.	2.5	11
88	Bloodstream infections in HIV-infected patients. Virulence, 2016, 7, 320-328.	4.4	38
89	HIV-1 RNA quantification in CRF02_AG HIV-1 infection: too easy to make mistakes. New Microbiologica, 2016, 39, 150-2.	0.1	6
90	Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. Biomedicine and Pharmacotherapy, 2015, 69, 233-236.	5.6	8

#	ARTICLE	IF	CITATIONS
91	Role of [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Diagnosis and Treatment of Sarcoidosis in an HIV-2-Infected Patient. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 868-869.	1.1	0
92	Therapeutic Management of Chronic Hepatitis B in Clinical Practice. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 228-234.	2.2	4
93	Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports. <i>International Journal of STD and AIDS</i> , 2015, 26, 831-834.	1.1	5
94	Epidemiological and Clinical Features of Hepatitis Delta in HBsAg-Positive Patients by HIV Status. <i>Antiviral Therapy</i> , 2015, 20, 193-197.	1.0	6
95	Pharmacokinetics of Lopinavir Determined with an ELISA Test in Youths with Perinatally Acquired HIV. <i>Indian Journal of Pediatrics</i> , 2014, 81, 856-60.	0.8	1
96	Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2014, 9, 41-51.	0.8	2
97	Pineal Germinoma in a Child with Interferon- β Receptor 1 Deficiency. Case Report and Literature Review. <i>Journal of Clinical Immunology</i> , 2014, 34, 922-927.	3.8	13
98	Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1862-1871.	3.0	20
99	Therapeutic Management of Chronic Hepatitis B in Clinical Practice: A Study in 505 Patients. <i>American Journal of Gastroenterology</i> , 2013, 108, S110.	0.4	0
100	Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 54-58.	1.2	16
101	Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 585-596.	4.4	68
102	Case report: Management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir. <i>Journal of Medical Virology</i> , 2012, 84, 1340-1343.	5.0	7
103	Will new antimicrobials overcome resistance among Gram-negatives?. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 909-922.	4.4	42
104	Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B. <i>Journal of Medical Virology</i> , 2011, 83, 1905-1908.	5.0	3
105	Epidemiology, Species Distribution, Antifungal Susceptibility and Outcome of Nosocomial Candidemia in a Tertiary Care Hospital in Italy. <i>PLoS ONE</i> , 2011, 6, e24198.	2.5	164